Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 7Recruiting 6Unknown 1Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 965Urinary Bladder Neoplasms 268Carcinoma, Renal Cell 253Kidney Neoplasms 146Breast Neoplasms 131Carcinoma, Transitional Cell 127Neoplasms 122Colorectal Neoplasms 100Ovarian Neoplasms 93Melanoma 85Carcinoma, Non-Small-Cell Lung 84Lung Neoplasms 83Neoplasm Metastasis 79Pancreatic Neoplasms 69Non-Muscle Invasive Bladder Neoplasms 68Uterine Cervical Neoplasms 59Stomach Neoplasms 56Head and Neck Neoplasms 52Endometrial Neoplasms 50Squamous Cell Carcinoma of Head and Neck 48Esophageal Neoplasms 44Adenocarcinoma 44Testicular Neoplasms 42Carcinoma, Hepatocellular 41Sarcoma 39Triple Negative Breast Neoplasms 34Liver Neoplasms 32Disease 31Colonic Neoplasms 29Metastatic Castration-resistant Prostate Cancer 25

Interventions

enzalutamide 4Docetaxel 2pembrolizumab 1olaparib 1lenvatinib 1inavolisib 1belzutifan 1abiraterone 1Prednisone 1PF06821497 1Lutetium-177 1Lutetium 1Gonadotropin-Releasing Hormone 1Etoposide 1Dexamethasone 1Carboplatin 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-Resistant Prostate Cancer × Genitourinary × Clear all
NCT06629779 2026-05-20

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Pfizer

Phase 3 Recruiting
900 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04986423 2026-05-08

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Zenith Epigenetics

Phase 2 Recruiting
200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT07287150 2026-05-06

InavoPC

Hoffmann-La Roche

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06318273 2026-04-08

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

AbbVie

Phase 1 Recruiting
230 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02861573 2026-02-17

KEYNOTE-365

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
1,200 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT06531499 2025-12-31

RADIODOSE

Novartis

Phase 1 Recruiting
106 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡